Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts

Alzheimer's and Dementia

Volumn 13, Issue 11, 2017, Pages 1226-1236

  Scheltens, Nienke M E ^a   Tijms, Betty M ^a   Koene, Teddy ^b   Barkhof, Frederik ^c,d,e   Teunissen, Charlotte E ^b   Wolfsgruber, Steffen ^f,g   Wagner, Michael ^f,g   Kornhuber, Johannes ^h   Peters, Oliver ⁱ   Cohn Sheehy, Brendan I ^j   Rabinovici, Gil D ^j   Miller, Bruce L ^j   Kramer, Joel H ^j   Scheltens, Philip ^a   van der Flier, Wiesje M ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU University Medical Centre ^*  (Netherlands)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF BONN   (Germany)

^g GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^h UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Alzheimer's disease; Atypical; Cognition; Heterogeneity; Neuropsychology; Subtypes

Indexed keywords

APOLIPOPROTEIN E; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E4; PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CALIFORNIA; COGNITIVE DEFECT; COHORT ANALYSIS; DISEASE MARKER; DISEASE SEVERITY ASSESSMENT; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; VALIDATION STUDY; CEREBROSPINAL FLUID; CLASSIFICATION; CLINICAL TRIAL; CLUSTER ANALYSIS; COMPLICATION; DENMARK; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; GENETICS; GERMANY; MENTAL HEALTH; MIDDLE AGED; MULTICENTER STUDY; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; CLUSTER ANALYSIS; COGNITION DISORDERS; COHORT STUDIES; DENMARK; DISEASE PROGRESSION; FEMALE; GERMANY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; UNITED STATES;

EID: 85019159802     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2017.03.002     Document Type: Article

References (48)

1. McKhann, G.M., Knopman, D.S., Chertkow, H., Hyman, B.T., Jack, C.R., Kawas, C.H., et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 263–269.
2. Gorno-Tempini, M.L., Hillis, A.E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S.F., et al. Classification of primary progressive aphasia and its variants. Neurology 76 (2011), 1006–1014.
3. Benson, D.F., Davis, R.J., Snyder, B.D., Posterior cortical atrophy. Arch Neurol 45 (1988), 789–793.
4. Crutch, S.J., Schott, J.M., Rabinovici, G.D., Boeve, B.F., Cappa, S.F., Dickerson, B.C., et al. Shining a light on posterior cortical atrophy. Alzheimers Dement 9 (2013), 463–465.
5. Ossenkoppele, R., Pijnenburg, Y.A., Perry, D.C., Cohn-Sheehy, B.I., Scheltens, N.M., Vogel, J.W., et al. The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. Brain 138 (2015), 2732–2749.
6. Van Der Flier, W.M., Schoonenboom, S.N., Pijnenburg, Y.A., Fox, N.C., Scheltens, P., The effect of APOE genotype on clinical phenotype in Alzheimer disease. Neurology 67 (2006), 526–527.
7. van der Vlies, A.E., Pijnenburg, Y.A., Koene, T., Klein, M., Kok, A., Scheltens, P., et al. Cognitive impairment in Alzheimer's disease is modified by APOE genotype. Dement Geriatr Cogn Disord 24 (2007), 98–103.
8. Smits, L.L., Tijms, B.M., Benedictus, M.R., Koedam, E.L., Koene, T., Reuling, I.E., et al. Regional atrophy is associated with impairment in distinct cognitive domains in Alzheimer's disease. Alzheimers Dement 10 (2014), S299–S305.
9. Ossenkoppele, R., Cohn-Sheehy, B.I., La Joie, R., Vogel, J.W., Möller, C., Lehmann, M., et al. Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. Hum Brain Mapp 36 (2015), 4421–4437.
10. Ossenkoppele, R., Mattsson, N., Teunissen, C.E., Barkhof, F., Pijnenburg, Y., Scheltens, P., et al. Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. Neurobiol Aging 36 (2015), 2340–2347.
11. Stopford, C.L., Snowden, J.S., Thompson, J.C., Neary, D., Variability in cognitive presentation of Alzheimer's disease. Cortex 44 (2008), 185–195.
12. Davidson, J.E., Irizarry, M.C., Bray, B.C., Wetten, S., Galwey, N., Gibson, R., et al. An exploration of cognitive subgroups in Alzheimer's disease. J Int Neuropsychol Soc 16 (2010), 233–243.
13. Libon, D.J., Drabick, D.A., Giovannetti, T., Price, C.C., Bondi, M.W., Eppig, J., et al. Neuropsychological syndromes associated with Alzheimer's/vascular dementia: a latent class analysis. J Alzheimers Dis 42 (2014), 999–1014.
14. Scheltens, N.M., Galindo-Garre, F., Pijnenburg, Y.A., van der Vlies, A.E., Smits, L.L., Koene, T., et al. The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. J Neurol Neurosurg Psychiatr 87 (2016), 235–243.
15. Brunet, J.P., Tamayo, P., Golub, T.R., Mesirov, J.P., Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A 101 (2004), 4164–4169.
16. Wang, Y.X., Zhang, Y.J., Nonnegative matrix factorization: a comprehensive review. IEEE Trans Knowl Data Eng 25 (2013), 1336–1353.
17. Carmona-Saez, P., Pascual-Marqui, R.D., Tirado, F., Carazo, J.M., Pascual-Montano, A., Biclustering of gene expression data by non-smooth non-negative matrix factorization. BMC Bioinformatics, 7, 2006, 78.
18. Shokrollahi, M., Krishnan, S., Dopsa, D.D., Muir, R.T., Black, S.E., Swartz, R.H., et al. Nonnegative matrix factorization and sparse representation for the automated detection of periodic limb movements in sleep. Med Biol Eng Comput 54 (2016), 1641–1654.
19. Folstein, M.F., Folstein, S.E., McHugh, P.R., “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975), 189–198.
20. van der Flier, W.M., Pijnenburg, Y.A., Prins, N., Lemstra, A.W., Bouwman, F.H., Teunissen, C.E., et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimers Dis 41 (2014), 313–327.
21. Verhage, F., Intelligence and religious persuasion. Ned Tijdschr Psychol 19 (1964), 247–254.
22. Kornhuber, J., Schmidtke, K., Frolich, L., Perneczky, R., Wolf, S., Hampel, H., et al. Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network. Dement Geriatr Cogn Disord 27 (2009), 404–417.
23. Kramer, J.H., Jurik, J., Sha, S.J., Rankin, K.P., Rosen, H.J., Johnson, J.K., et al. Distinctive neuropsychological patterns in frontotemporal dementia, semantic dementia, and Alzheimer disease. Cogn Behav Neurol 16 (2003), 211–218.
24. Van Buuren, S., Groothuis-Oudshoorn, K., MICE: multivariate imputation by chained equations in R. J Stat Softw 45 (2011), 1–67.
25. Van Buuren, S., Flexible imputation of missing data, vol. 20125245, 2012, CRC Press, Boca Raton, FL.
26. Rubin, D.B., Multiple imputation for nonresponse in surveys. 2009, John Wiley & Sons, Hoboken, NJ, USA.
27. Marshall, A., Altman, D.G., Holder, R.L., Royston, P., Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol, 9, 2009, 57.
28. Scheltens, P., Launer, L.J., Barkhof, F., Weinstein, H.C., van Gool, W.A., Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol 242 (1995), 557–560.
29. Koedam, E.L., Lehmann, M., van der Flier, W.M., Scheltens, P., Pijnenburg, Y.A., Fox, N., et al. Visual assessment of posterior atrophy development of a MRI rating scale. Eur Radiol 21 (2011), 2618–2625.
30. Fazekas, F., Chawluk, J.B., Alavi, A., Hurtig, H.I., Zimmerman, R.A., MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 149 (1987), 351–356.
31. Jack, C.R., Bernstein, M.A., Fox, N.C., Thompson, P., Alexander, G., Harvey, D., et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 27 (2008), 685–691.
32. Fischl, B., FreeSurfer. Neuroimage 62 (2012), 774–781.
33. Schwarz, C.G., Fletcher, E., DeCarli, C.S., Carmichael, O., Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIRs. Inf Process Med Imaging 21 (2009), 239–251.
34. Ewers, M., Teipel, S.J., Dietrich, O., Schönberg, S.O., Jessen, F., Heun, R., et al. Multicenter assessment of reliability of cranial MRI. Neurobiol Aging 27 (2006), 1051–1059.
35. Patenaude, B., Smith, S.M., Kennedy, D.N., Jenkinson, M., A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage 56 (2011), 907–922.
36. Smith, S.M., Jenkinson, M., Woolrich, M.W., Beckmann, C.F., Behrens, T.E.J., Johansen-Berg, H., et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 23 (2004), S208–S219.
37. Lewczuk, P., Kornhuber, J., Wiltfang, J., The German Competence Net Dementias: standard operating procedures for the neurochemical dementia diagnostics. J Neural Transm (Vienna) 113 (2006), 1075–1080.
38. Duits, F.H., Teunissen, C.E., Bouwman, F.H., Visser, P.J., Mattsson, N., Zetterberg, H., et al. The cerebrospinal fluid “Alzheimer profile”: easily said, but what does it mean?. Alzheimers Dement 10 (2014), 713–723.e2.
39. Shaw, L.M., Vanderstichele, H., Knapik-Czajka, M., Clark, C.M., Aisen, P.S., Petersen, R.C., et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65 (2009), 403–413.
40. Gaujoux, R., Seoighe, C., A flexible R package for nonnegative matrix factorization. BMC Bioinformatics, 11, 2010, 367.
41. Pascual-Montano, A., Carazo, J.M., Kochi, K., Lehmann, D., Pascual-Marqui, R.D., Nonsmooth nonnegative matrix factorization (nsNMF). IEEE Trans Pattern Anal Mach Intell 28 (2006), 403–415.
42. van der Vlies, A.E., Koedam, E.L., Pijnenburg, Y.A., Twisk, J.W., Scheltens, P., Van Der Flier, W.M., Most rapid cognitive decline in APOE epsilon4 negative Alzheimer's disease with early onset. Psychol Med 39 (2009), 1907–1911.
43. Smits, L.L., Pijnenburg, Y.A., van der Vlies, A.E., Koedam, E.L., Bouwman, F.H., Reuling, I.E., et al. Early onset APOE E4-negative Alzheimer's disease patients show faster cognitive decline on non-memory domains. Eur Neuropsychopharmacol 25 (2015), 1010–1017.
44. van der Flier, W.M., Clinical heterogeneity in familial Alzheimer's disease. Lancet Neurol 15 (2016), 1296–1298.
45. Braak, H., Braak, E., Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82 (1991), 239–259.
46. van der Flier, W.M., Pijnenburg, Y.A., Fox, N.C., Scheltens, P., Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele. Lancet Neurol 10 (2011), 280–288.
47. Murray, M.E., Graff-Radford, N.R., Ross, O.A., Petersen, R.C., Duara, R., Dickson, D.W., Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 10 (2011), 785–796.
48. Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., Naj, A.C., Sims, R., Bellenguez, C., et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 45 (2013), 1452–1458.